Full-Time

Manufacturing Engineer

Strategic Initiatives

Posted on 9/4/2025

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Compensation Overview

$81.3k - $106.7k/yr

Bridgewater Township, NJ, USA

Hybrid

Hybrid work arrangement. In-office days per week are not specified in the posting. Located in Raritan, NJ, USA.

Category
Mechanical Engineering (1)
Requirements
  • Bachelor’s degree in Engineering, related field, or equivalent experience is required.
  • A minimum of 6 years of within a cGMP environment in the biotech/biopharma industry is required.
  • A minimum of 4 years of cell therapy experience is preferred.
  • A minimum of 3 years of engineering experience is required.
  • A minimum of 2 years of tech transfer experience is preferred.
  • A minimum of 2 years of facility/process qualification experience is preferred.
  • A minimum of 2 years of commissioning/qualification experience is preferred.
  • Background in a heavily regulated pharmaceutical environment with adherence to strict regulatory guidelines and internal compliance policies.
  • In depth understanding of cleanroom manufacturing, aseptic manufacturing processes, and common challenges.
  • Must exhibit strong Leadership skills and ability to effectively communicate with a wide variety of stakeholders across the organization.
  • Ability to work independently and successfully, prioritize and manage multiple tasks simultaneously, integrate cross-functional issues and balance competing priorities effectively.
  • Must be able to manage shifting priorities to meet critical deadlines in a fast paced and dynamic, growing environment.
  • Strong analytical, problem solving and critical thinking skills and the ability to lead as a change agent to promote flexibility, creativity, and accountability.
  • An ability to build strong partnerships and effectively integrate with external collaborators to drive projects/programs forward in a matrixed environment.
  • Ability to tailor communication to convey detailed information to a wide variety of audiences.
  • Strong technical writing skills to author manufacturing SOP’s or technical documentation as needed.
  • Experience with process modelling and optimization.
  • Experience with new facility design or design of existing facility upgrades.
  • Experience with new facility startup or new equipment/technology set up.
  • Experience with equipment, facility, and process qualification activities including, but not limited to IQ/OQ/PQ, EMPQ, APS, PPQ, preferred.
  • Experience with change management/change control and quality systems.
  • Experience with FMEA and risk assessment tools.
  • Experience with user requirement documentation and factory/site acceptance testing.
  • Experience interfacing with vendors to assess novel equipment or technology.
  • Experience with tech transfer at early and mature stages of technology development.
  • Thorough knowledge of regulatory requirements such as 21 CFR Parts 210, 211, 11, EU Annex 11.
  • #Li-BZ1
  • #Li-Hybrid
Responsibilities
  • This individual’s primary responsibility will be support of manufacturing process optimization through process modelling, new technology integration, and various site expansion initiatives.
  • Establish relationships and work cross functionally with local and global stakeholders including but not limited to Operations, MSAT, Facilities, C&Q, Project Management, and Quality.
  • Work closely with Sr. Manager, Strategic Initiatives to support various strategic initiatives focusing on site expansion and evolution of the manufacturing facility.
  • Establish expertise on site manufacturing processes to effectively support the process improvements and new technology integration, while ensuring alignment with site capacity goals.
  • Display critical thinking skills to independently evaluate manufacturing process/facility limitations, to effectively assess and support novel solutions.
  • Analyze the manufacturing process to identify areas of inefficiency and develop novel solutions to optimize the manufacturing process.
  • Own/support development of site operational models to better understand and assess resource utilization, equipment utilization, change impact, etc.
  • Support assessment of facility fitness, and design of facility upgrades to support integration of new technology.
  • Ensure project deliverables are executed in an effective, efficient, and compliant manner.
  • Participate in Risk Assessments, FMEAs, and system/data process mapping activities.
  • Execute, own, assess and participate in the creation, revision and review of change controls, SOPs, and other documentation.

Legend Biotech develops and commercializes cell therapies for serious diseases, including hematologic cancers and solid tumors, with a focus on personalized medicine. Its therapies, like CAR-T treatments, work by collecting a patient’s cells, engineering them to target cancer cells, expanding them, and reinfusing them into the patient. The company differentiates itself by using multiple technology platforms (technology-agnostic) and pursuing a broad pipeline, including exclusive global licenses for CAR-T therapies. Its goal is to bring effective, personalized cell therapies to market, improve outcomes for hard-to-treat cancers, and maintain transparent communication with investors while expanding globally.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI sales hit $597M in Q1 2026, up 62% YoY across 18 markets.
  • J&J invests $1B in Pennsylvania facility, boosting CARVYKTI U.S. capacity.
  • Scientific board with Carl June guides pipeline into next-gen cell therapies.

What critics are saying

  • J&J's Montgomery facility cuts Legend's CARVYKTI manufacturing share in 12 months.
  • Gross margins fall to 41% in Q1 2026 from ramp-up costs eroding profits.
  • BMS Abecma grabs 25% more second-line myeloma share via faster FDA approval.

What makes Legend Biotech unique

  • Cilta-cel uses dual BCMA-targeting single-domain antibodies for deeper multiple myeloma responses.
  • LCAR-AIO tri-specific CAR-T targets CD19, CD20, and CD22 for relapsed B-cell lymphomas.
  • LB2102 DLL3 CAR-T with Novartis T-Charge enables in-body expansion for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Mar 10th, 2026
Legend Biotech's CARVYKTI hits $555M Q4 sales, reaches profitability with 10,000-dose capacity

Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in Q4, up 66% year-over-year. Management said CARVYKTI reached profitability in 2025 and expects enterprise-wide profitability in 2026. The therapy is now available in 14 global markets across 294 treatment sites. Legend has installed manufacturing capacity for 10,000 doses, with plans to expand to 20,000 alongside Johnson & Johnson. Manufacturing success rates range from 97% to 99%. Clinical data show median progression-free survival of 50.4 months in triple-class-exposed patients with three prior lines of therapy. Approximately 65% of patients are now treated in the second-to-fourth-line setting, reflecting earlier use in the treatment course. Legend ended 2025 with $949 million in cash and recorded adjusted net income of $2.5 million in Q4.

Yahoo Finance
Mar 10th, 2026
Legend Biotech reports $1.9B CARVYKTI sales for 2025, treats over 10,000 patients

Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in the fourth quarter and $1.9 billion for the full year 2025, achieving franchise profitability. The company has treated over 10,000 patients with its CAR-T therapy and expanded availability to 294 sites across 14 markets worldwide. The company completed expansion of its Raritan facility, creating the largest cell therapy manufacturing site in the United States with capacity to support 10,000 patients annually. Legend Biotech also advanced its pipeline, opening a 31,000-square-foot R&D facility in Philadelphia and dosing the first patient for its in vivo candidates. As of 31 December 2025, Legend Biotech held $949 million in cash and cash equivalents, providing financial runway beyond 2026 when it expects to achieve company-wide operating profit.

Yahoo Finance
Feb 3rd, 2026
Legend Biotech shares drop 46% in 3 months despite $72 fair value estimate

Legend Biotech has raised $120 million in a Series C round led by Ribbit Capital, valuing the pre-revenue AI startup at $1.45 billion. Sequoia and Kleiner Perkins participated, alongside new backer Emerson Collective, bringing total capital raised to $295 million. Co-founded by Robinhood CEO Vlad Tenev, Harmonic develops "Mathematical Superintelligence" that eliminates AI hallucinations by requiring outputs in verifiable Lean4 programming code. Its Aristotle model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, the company currently offers Aristotle via free API to mathematicians and researchers. It plans future commercialisation targeting safety-critical sectors including aerospace, automotive and finance, where error-free logic is essential.

BioSpace
Jan 29th, 2026
Biotech's Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026

Biotech's next chapter: asset-centric deals and shifting alpha at JPM 2026. January 29, 2026 | After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation. Now that the sound and fury of the J.P. Morgan Healthcare Conference have subsided, investors are taking a step back to evaluate for 2026 the acquisition and capital environment, the buzzy therapeutic spaces and lingering risk factors. Biotech is emerging from a multiyear slump into a new cycle driven by fundamental progress and late-stage assets, said Roderick Wong, managing partner and chief investment officer at New York-based RTW Investments. Although JPM 2026 felt light on headline megadeals, record-setting M&A rumors before the conference around Revolution Medicines (reported to be in talks with Merck and AbbVie) and Abivax (with Eli Lilly speculation takeover) underscored strong demand for high quality, late-stage development assets, Wong said. Actual announced deals (e.g., Eli Lilly - Ventyx Biosciences, GlaxoSmithKline - RAPT Therapeutics, Boston Scientific - Penumbra) reinforced that asset-centric transactions are with clear blockbuster or strategic potential are the most interesting, Wong said. From RTW's vantage point and reinforced by several VC conversations on the sidelines of JPM26, asset-focused companies remain more attractive than pure platform or technology plays in the current environment. Hot therapeutic investment spaces. Key disease areas of focus include oncology (pancreatic, breast, bladder), where several programs could reset standards of care and address major unmet needs, noted Stephanie Sirota, partner and chief business officer at RTW. Obesity is another major theme, with anticipation around the first true small-molecule pill from Eli Lilly and a next wave of novel mechanisms, Wong said. One of RTW's portfolio companies, Corxel, announced on January 23 a $287 million Series D fundraising. Neuroscience/CNS has seen a sharp sentiment shift, with investors leaning back into space after years of limited innovation, Wong and Sirota agreed. Their comments echo those heard on the sidelines of JPM26; that advances in biomarkers, brain mapping and AI, as well as a rapidly aging population, support investment in the space. Psychedelics exemplify a potential paradigm shift in depression treatment modality, Wong said, with Compass Pathways' Phase III data and a possible near-term launch supporting nondaily, episodic treatment models. The cultural and medical shift in psychedelic therapeutic is one of the topics explored in the RTW's latest book "Innovation is the Best Medicine." FDA remains a risk factor. The degree of policy risk for the biopharma sector has declined significantly since the start of the Trump administration last year, Wong said. At the time, major uncertainties surrounded tariffs, manufacturing reshoring and Most Favored Nations drug pricing negotiations. What has evolved are reasonable resolutions that have been neutral to modestly negative rather than worstcase scenarios, he added. There have been many discussions around the chaotic year at the FDA in 2025, including a revolving door of senior staff members. The main remaining structural risk, Wong said, is FDA behavior in "edge cases," particularly in rare diseases and emerging modalities like gene and cell therapies, using nontraditional trial designs, surrogate endpoints or single arm studies. Last year's players in this space saw negative feedback or rejection, discussed in greater depth in the RTW book. RTW is responding by being more conservative around such edge case programs, which it expects will depress capital flows into some rare disease and early modality assets. Alpha stacking model. The firm frames its investment process as "alpha stacking:" starting with rigorous fundamental equity analysis (science underwriting plus commercial forecasting) and layering on multiple, evolving sources of information and assessment, Sirota said. This includes collecting information on policy, considering transactional and operational models, as well as what is compelling from a buyer perspective. The firm has built deep therapeutic specialization plus functional expertise (e.g., IP, geography such as China) to move beyond headline-driven views of risk and opportunity. RTW has also invested internally in data science, automation and AI to enhance its research process, they agreed. Ultimately, investment is always evolving, Wong said. He noted that a scientific background at one was the advantage - an alpha - one had when investing, but that's become understood. Rather, alpha stacking is now about intentionally trying to understand where the advantages lie and staying on top of these evolving factors. In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW's Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how "alpha stacking" shapes their investment edge in an age of chronic uncertainty. January 29, 2026

Stock Titan
Aug 18th, 2025
[6-K] Legend Biotech Corporation American Current Report (Foreign Issuer)

On August 18, 2025, Legend Biotech Corporation announced the appointment of Carlos Santos as the Company's Chief Financial Officer ("CFO").

INACTIVE